Meeting
2022 ASCO Annual Meeting
A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.
Authors
Jiuwei Cui
Cancer Center, First Hospital of Jilin University, Changchun, China
Jiuwei Cui , Naifei Chen , Chengfei Pu , Lingling Zhao , Ning Li , Chang Wang , Yusheng Huang , SuXia Luo , Xun Li , Zhenzhou Yang , Jun Bie , Ruihong Zhu , Xi Huang , Haiyang Tang , Tingting Liang , Yizhuo Wang , Eugene Paul Kennedy , Zhao Wu , Yongping Song , Lei Xiao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
ChiCTR2100053828
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3582)
DOI
10.1200/JCO.2022.40.16_suppl.3582
Abstract #
3582
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.
First Author: Lei Xiao
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li